



A Revolutionary Toothpaste Based Approach To Food Allergy Immunotherapy



Disclosures



Important Information

The information regarding the proposed private placement offering by Intrimmune Therapeutics is being provided to you on a confidential basis only and should not be disclosed to anyone other than your professional advisers on a confidential basis for purposes related to your interest in the company. This information should not be divulged, reproduced or disseminated without our consent.

Only qualified “accredited investors” as defined in Regulation D under the Securities Act of 1933, as amended will be permitted to participate in the proposed offering. Additional suitability requirements may apply.

These materials do not constitute either an offer to sell or an offer to purchase securities. Any purchase of securities will be made pursuant to and governed by a subscription agreement between the company and the investor, and the company will have the right to accept or reject subscriptions in its sole discretion. There is no minimum amount of subscriptions we must receive before we close on any subscription.

We will make available to any prospective purchaser and such person’s advisers the opportunity to ask questions and receive answers concerning the terms and conditions of the proposed offering, the company, or any other relevant matters, and to obtain any additional information to the extent the company possesses such information.

Any investment in Intrimmune Therapeutics involves a high degree of risk. You should carefully read all of the risk factors attached to the subscription agreement prior to any investment. There is no assurance that an investment will be profitable at any time.

Neither Intrimmune Therapeutics nor any of its equity interests are registered with the Securities and Exchange Commission or the securities regulator of any state.

This communication contains forward looking-statements, which can be identified by, among other things, the use of forward-looking language, such as the words “plans,” “intends,” “believes,” “expects,” “anticipates,” “estimates,” “projects,” “potential,” “may,” “will,” “would,” “could,” “should,” “seeks,” or “scheduled to,” or other similar words, or by discussion of strategy or intentions. Forward-looking statements are based upon management’s present expectations or strategies regarding the future and are subject to known and unknown risks and uncertainties that could cause actual results, events or developments to be materially different from those indicated in such forward-looking statements. No assurance can be given that the future results covered by the forward-looking statements will be achieved. The information contained herein and in the documents enclosed herewith is current only as of the date hereof and you should not, under any circumstances, assume that there has not been any change in the matters discussed herein or in the documents enclosed herewith since the date hereof.

Our mission



INTROMMUNE is developing *safe* and *effective* options for individuals suffering with food allergy so that they and their loved ones can live their lives *without fear*



Introducing a novel approach to allergy desensitization

Delivering therapeutic agents through oral mucosal immunotherapy (OMIT)



Embedded food derived
allergen proteins



Administered at the same time
patients brush their teeth



Convenient daily
immunotherapy

Food allergies are a rising concern with limited options

Food allergies affect **32mm** Americans
(220mm+ worldwide)



Total cost of childhood food allergies -
\$25B/year



9 common foods account for
over **90%** of all food allergies



Current *best* option is **avoidance**




Intrommune's first product will
address peanut allergies




The **oral cavity** is the natural classroom where
the body learns its relationship with food



OMIT targets entire oral mucosa, optimizing exposure to oral immune cells






Intrommune toothpaste delivers allergen protein


Toothpaste slurry coats the mouth so more allergen protein can bind with cells on the surface of the oral mucosal epithelium. The opposing charges of the protein and surface cells attracts them to each other to form a strong bond.






Langerhans Cells process and display allergen proteins

Oral Langerhans cells capture allergen protein as it diffuses into the oral mucosa, displaying key identifiers on their surface before travelling to regional lymph nodes.





Oral Mucosal Epithelium



Langerhan cells trigger the re-education of the immune system


Once in the regional lymph nodes Langerhans cells activate naive T cells causing them to differentiate into either T regulatory (Treg) cells or T helper type 1 (Th1) cells.





Differentiated T Cells decrease the allergic response

Treg and Th1 cells travel through lymph vessels and distribute themselves throughout the mucosa of the aerodigestive tract where they decrease the allergic immune response the next time there is exposure to the specific allergen protein.



Intrommune OMIT: A clinically de-risked biotech opportunity



INTROMMUNE
THERAPEUTICS



100,000 new peanut allergy (PA) sufferers in the U.S. per year (\$1B new market entrants)



Substantial upside with multiple near-term liquidity events



Low development risk



Patients/Practitioners/Payers seeking *protection* from accidental exposure



Significant *social impact*



Multi-product / licensing opportunities



Significant improvement over comparators - comp acquired for \$2.6B

OMIT – Peanut key investment metrics

OPPORTUNITY



6M

U.S. Peanut
Allergic Pop



1.6M

U.S. Peanut
Allergic
Children



1M

Diagnosed
(Aged 4 – 18 years)



690K

Immediate
serviceable market
for Intromune*

UNMET NEED

TAM:
\$7,369,200,000

Insurance Coverage:
Yes

OIT Price/Year Per Patient:
\$10,680

Solutions / Expectations

- ✓ Reduce adverse effects
- ✓ Better adherence
- ✓ Increased efficacy
- ✓ Multi-product platform

Intellectual property



Exclusive global
IP license for
food allergy
immunotherapy



Global portfolio
*(Including U.S., EU,
China, India, Japan)*



Two patent
families – 35
patents to date

- Toothpaste + allergens for immunotherapy
- Formulations to stabilize allergens



Global protection
through 2034

- Potential to extend to 2042



Additional IP
grants expected,
and new filings
planned

Intrommune Peanut OMIT — Clear approval pathway



Phase 1b Study
Underway
(INT301-101)



CRO engaged – Circuit Clinical

IND filed & accepted



Highly collaborative

No toxicology review (API is peanut protein)

No pharmacokinetics due to route of administration

No animal models

Milestones & goals

Series A \$5.4mm (closed)

INVESTORS:

Robin Hood Ventures / Timberline Holdings / Chemical Angel Network / Red Bear Angels

ACCOMPLISHED:

- Exclusive OMIT rights for food allergy
- Developed INT301 formulation
- IND accepted
- Phase 1b

INVESTORS:

Focus on strategic partners (investors), private capital, and venture

GOALS:

- Launch Phase 2 (2022)
- Chemistry, Manufacturing & Controls (CMC) implementation
- Continue reconstituting management and advisory board
- Media and professional branding / marketing push
- Identify liquidity and market opportunities

Series B \$30mm

Valuation projections: post-phase 1b

Target Valuation:
\$300-400mm

Expected target *6 months*

With significant upside:

- Safe, simple and controlled manufacture
- Positive *social* and *health* impact
- Numerous *synergies* and *partnership*



Valuation: **\$145mm**

- Complicated manufacturing
- No public comparables at time
- Limited evidence of efficacy



Valuation: **\$300mm**
with additional 10% royalties

- DNA vaccine – high risk
- Potential for germline effects



Valuation projections: post-phase 2

Target Valuation:
\$1B+

Expected target H2 2023

With significant upside:

- Numerous *synergies* and *partnerships*
- Expectation for multi-allergen innovation with parallel development tracks



Valuation: \$4B+

- Believed to have received multiple offers when considered a safe and effective alternative
- Regulatory complications



Valuation: \$650mm

- Known high risks
- Epinephrine use, GI and EoE
- Inefficient application



Key comparator – Aimmune Therapeutics

OMIT makes lifelong usage easy *without* the adverse events observed with OIT



Acquired for \$2.6B

- OIT technology with *NO revenue when acquired*
- *Inconvenient delivery*
 - Patients must add peanut powder to semi-solid food daily
- *Significant adverse event profile*
 - *Increased* systemic allergic reactions
 - *Increased* discontinuation due to AEs
 - *Increased* reports of EoE (chronic, allergic inflammatory disease)
- *Restrictive REMS* (Risk Evaluation and Mitigation Strategy)
- *Increases risk* of emergency epinephrine requiring ER visit
- Many patients will have to take product for life

Key comparator – DBV Technologies

OMIT is the *only* safe and effective immunotherapy under development



\$600mm valuation*

EPIT technology received an FDA complete response letter

- Skin patch containing peanut proteins *irritates* skin
- Issues with *patch adhesion*
- *Reworking* of CMC required
- Continued extended *delay*, approval uncertain
- Corporate *restructuring* occurring, *making talent available*
- *Efficacy low*
 - 2 years of constant use before protection potentially achieved
 - Phase 3 efficacy endpoint missed

Management



Michael Nelson, JD

Chief Executive
Officer



Stuart Loesch

Chief Commercial Officer



Eric First, M.D. FAIS

Chief Development
Officer




Alain Van Loo

Chief Operating
Officer



Erick Berglund, PhD.

Chief Science Officer




Keith James, MBA CPA

Chief Financial
Officer



WILLKIE FARR & GALLAGHER LLP



Advisory Board



BUSINESS

[Jotin Marango, MD, PhD](#) | Corporate Strategy & Finance Advisor, Chair

[Tonya Winders, MBA](#) | Stakeholder Outreach Advisor

[Terrence Tormey](#) | Business Development Advisor

[Greg Van Gasse, MBA](#) | Marketing Advisor

[Jack Levitt, MBA](#) | Executive Development Advisor

[David Sanders](#) | Government Affairs Advisor

[Mark Durham](#) | Human Capital Advisor

[Prof. Dr. Sergi X. Trilla](#) | Business & Science Advisor

SCIENCE

[Professor William Reisacher, MD](#) | Inventor of OMIT; Senior Scientific Advisor, Chair

[Greg Plunkett, PhD](#) | CMC Advisor

[Anthony Robinson, CRNP, MBA](#) | Clinical Advisor

[Gerry Kugel, DMD, PhD](#) | Dental Advisor

[Prof. Dr. Sergi X. Trilla](#) | Business & Science Advisor

Intrommune opportunity at-a-glance



Revolutionary *patented* commercial grade *toothpaste* drug-delivery platform



Greater *efficacy* expected

- 12x mucosal coverage in comparison to SLIT
- Targets *entire* oral cavity surface
- Contacts more *optimal* areas of mouth
- *Dosing* >2mg (2mg = 300mg OIT)



Positive financials

- Series A: \$5.4mm
- Series B (planned October 2021): \$30mm



Expected to be *safe*, no epinephrine use



Built-in adherence with daily routine

- *No adverse taste* or difficulty in administration
- Reinforces *positive habits* – oral health
- *Reduces anxiety* / Don't have to feel afflicted



Platform for multiple food allergy treatments



Thank you